Galmed Pharmaceuticals Ltd. (GLMD) 6.80 $GLMD
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Galmed, Perrigo Tie Up for Mass Production of Aramchol API - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:30PM CST
Galmed Pharmaceuticals Ltd. (GLMD) signed a manufacturing services agreement with Perrigo for the large-scale production of the API in Galmed's aramchol.
PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
PR Newswire - Wed Jan 28, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it has entered into a Manufacturing Services Agreement with Perrigo API Ltd., a subsidiary of Perrigo Company plc (NYSE: PRGO) ("Perrigo" , for the large-scale production of the active pharmaceutical ingredient ("API" of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.
PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals to Present at the Biotech Showcase(TM)
PR Newswire - Tue Jan 06, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced that Josh Blacher, Chief Financial Officer, will present a company overview at the Seventh Annual Biotech Showcase(TM) conference in San Francisco, California on Wednesday, January 14, 2015 at 10:00 AM Pacific Standard Time. The presentation will be available live via webcast at http://galmedpharma.investorroom.com/.
GLMD: 6.80 (+0.03)
New finance chief at Galmed
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:18AM CST
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals Announces the Appointment of Josh Blacher as Chief Financial Officer
PR Newswire - Mon Jan 05, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced that it has appointed Josh Blacher as Chief Financial Officer, effective as of January 1, 2015. Mr. Blacher replaces Mr. Ray Morris, who previously served Galmed in such capacity through December 31, 2014.
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals: A Compelling Trade For Your New Year Portfolio
Alexander Maxwell - at Seeking Alpha - Sat Dec 27, 7:07AM CST
GLMD: 6.80 (+0.03), ICPT: 209.12 (+7.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:45AM CST
RBY: 1.11 (unch), FATE: 5.00 (-0.07), IMDZ: 25.34 (+1.20), RXII: 1.20 (-0.03), GLMD: 6.80 (+0.03), TBIO: 2.91 (+0.01), SIM: 8.29 (+0.24), PHMD: 1.68 (+0.04), IMGN: 7.19 (unch), PETX: 16.52 (-0.10), NQ: 3.95 (-0.03), OTIC: 31.14 (+0.13), VHC: 5.53 (+0.09), FINL: 23.51 (-0.32), BBLU: 1.26 (+0.09), TRXC: 2.86 (-0.11), BAS: 7.28 (+0.62), ENRJ: 2.81 (+0.06), TNK: 5.50 (+0.10)
The 2015 Calendar Of NASH Trial Catalysts III: Galmed And Intercept
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 11:23AM CST
GLMD: 6.80 (+0.03), ICPT: 209.12 (+7.12)
Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers
PR Newswire - Mon Dec 01, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced the completion of the statistical analysis of a pharmacokinetic (PK) study of three doses, including two high doses (400 mg and 600 mg), of its drug candidate, aramchol, in 66 healthy adult male volunteers. No Serious Adverse Events (SAEs) were observed in the study.
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones
PR Newswire - Thu Nov 13, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today the first administration of its drug candidate, aramchol, in its proof-of-concept Phase IIa clinical trial for the treatment of newly formed cholesterol gallstones following bariatric surgery.
GLMD: 6.80 (+0.03)
Galmed Pharmaceutical's (GLMD) CEO Allen Baharaff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:16AM CST
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals Provides Business Update and Reports Year-To-Date 2014 Financial Results
PR Newswire - Wed Nov 12, 6:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced select third quarter 2014 and recent corporate highlights, as well as financial results for the nine months ended September 30, 2014.
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals to Host Key Opinion Leader Meeting and Webcast on November 7, 2014 in New York City
PR Newswire - Wed Nov 05, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it will host a Key Opinion Leader breakfast meeting on Friday, November 7, 2014, from 8:00 a.m. to 9:30 a.m. Eastern Standard Time at the NY Palace Hotel in New York City.
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals Third Quarter 2014 Conference Call and Webcast Scheduled for Wednesday, November 12, 2014
PR Newswire - Wed Nov 05, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it will host a conference call and webcast on Wednesday, November 12, 2014 to discuss results for the period ended September 30, 2014 and to provide an update on current developments with respect to its clinical program for aramchol.
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol's Effect on Endothelial Function
PR Newswire - Mon Sep 29, 8:13AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT(TM) devices and accessories from Itamar Medical Ltd. (TASE: ITMR) ("Itamar Medical" , a publicly-traded medical device company whose technology has been cleared by the U.S. Food and Drug Administration, or the FDA, for endothelial, or arterial, function assessment, which is a novel risk marker for cardiovascular disease.
GLMD: 6.80 (+0.03)
Galmed's Aramchol Gets Fast-Track Designation in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:45PM CDT
Galmed Pharmaceuticals Ltd. (GLMD) announced that the FDA has granted fast track status to aramchol for the treatment of non-alcoholic steato-hepatitis.
LCI: 57.78 (-0.91), ENDP: 84.01 (+1.12), GLMD: 6.80 (+0.03), ENTA: 33.30 (-0.44)
Galmed Pharmaceuticals acquires US FDA's Fast Track Designation for Aramchol for NASH
M2 - Wed Sep 24, 6:24AM CDT
Biopharmaceutical company Galmed Pharmaceuticals (NasdaqCM :GLMD) reported on Tuesday the receipt of the US Food and Drug Administration's Fast Track Designation for aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.
GLMD: 6.80 (+0.03)
Market Maker Surveillance Report. RITT, JRJC, UQM, GLMD, SINO, ECTE, Winning Stocks With Lowest Price Friction For Tuesday, September 23rd 2014
M2 - Wed Sep 24, 3:42AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4582 companies with "abnormal" market making, 1424 companies with positive Friction Factors and 3854 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), China Finance Online Co Ltd (NASDAQ:JRJC), UQM Technologies Inc (NYSE:UQM), GOLD MEDAL RES LTD (NASDAQ:GLMD), Sino-Global Shipping America Ltd (NASDAQ:SINO), Echo Therapeutics Inc (NASDAQ:ECTE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ECTE: 2.62 (+0.06), JRJC: 5.46 (+0.16), GLMD: 6.80 (+0.03), UQM: 0.97 (+0.01), RITT: 1.29 (unch), SINO: 1.50 (unch)
Why Galmed Pharmaceuticals (GLMD) Stock Is Surging Today
at The Street - Tue Sep 23, 2:50PM CDT
Shares of Galmed Pharmaceuticals (GLMD) soared Tuesday after the company announced the FDA had given Fast Track Designation to its drug candidate aramchol.
GLMD: 6.80 (+0.03)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Galmed, Perrigo Tie Up for Mass Production of Aramchol API - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:30PM CST
Galmed Pharmaceuticals Ltd. (GLMD) signed a manufacturing services agreement with Perrigo for the large-scale production of the API in Galmed's aramchol.
PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
PR Newswire - Wed Jan 28, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it has entered into a Manufacturing Services Agreement with Perrigo API Ltd., a subsidiary of Perrigo Company plc (NYSE: PRGO) ("Perrigo" , for the large-scale production of the active pharmaceutical ingredient ("API" of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals to Present at the Biotech Showcase(TM)
PR Newswire - Tue Jan 06, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced that Josh Blacher, Chief Financial Officer, will present a company overview at the Seventh Annual Biotech Showcase(TM) conference in San Francisco, California on Wednesday, January 14, 2015 at 10:00 AM Pacific Standard Time. The presentation will be available live via webcast at http://galmedpharma.investorroom.com/. GLMD: 6.80 (+0.03)
New finance chief at Galmed
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:18AM CST
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals Announces the Appointment of Josh Blacher as Chief Financial Officer
PR Newswire - Mon Jan 05, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced that it has appointed Josh Blacher as Chief Financial Officer, effective as of January 1, 2015. Mr. Blacher replaces Mr. Ray Morris, who previously served Galmed in such capacity through December 31, 2014. GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals: A Compelling Trade For Your New Year Portfolio
Alexander Maxwell - at Seeking Alpha - Sat Dec 27, 7:07AM CST
GLMD: 6.80 (+0.03), ICPT: 209.12 (+7.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:45AM CST
RBY: 1.11 (unch), FATE: 5.00 (-0.07), IMDZ: 25.34 (+1.20), RXII: 1.20 (-0.03), GLMD: 6.80 (+0.03), TBIO: 2.91 (+0.01), SIM: 8.29 (+0.24), PHMD: 1.68 (+0.04), IMGN: 7.19 (unch), PETX: 16.52 (-0.10), NQ: 3.95 (-0.03), OTIC: 31.14 (+0.13), VHC: 5.53 (+0.09), FINL: 23.51 (-0.32), BBLU: 1.26 (+0.09), TRXC: 2.86 (-0.11), BAS: 7.28 (+0.62), ENRJ: 2.81 (+0.06), TNK: 5.50 (+0.10)
The 2015 Calendar Of NASH Trial Catalysts III: Galmed And Intercept
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 11:23AM CST
GLMD: 6.80 (+0.03), ICPT: 209.12 (+7.12)
Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers
PR Newswire - Mon Dec 01, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced the completion of the statistical analysis of a pharmacokinetic (PK) study of three doses, including two high doses (400 mg and 600 mg), of its drug candidate, aramchol, in 66 healthy adult male volunteers. No Serious Adverse Events (SAEs) were observed in the study. GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones
PR Newswire - Thu Nov 13, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today the first administration of its drug candidate, aramchol, in its proof-of-concept Phase IIa clinical trial for the treatment of newly formed cholesterol gallstones following bariatric surgery. GLMD: 6.80 (+0.03)
Galmed Pharmaceutical's (GLMD) CEO Allen Baharaff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:16AM CST
GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals Provides Business Update and Reports Year-To-Date 2014 Financial Results
PR Newswire - Wed Nov 12, 6:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced select third quarter 2014 and recent corporate highlights, as well as financial results for the nine months ended September 30, 2014. GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals to Host Key Opinion Leader Meeting and Webcast on November 7, 2014 in New York City
PR Newswire - Wed Nov 05, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it will host a Key Opinion Leader breakfast meeting on Friday, November 7, 2014, from 8:00 a.m. to 9:30 a.m. Eastern Standard Time at the NY Palace Hotel in New York City. GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals Third Quarter 2014 Conference Call and Webcast Scheduled for Wednesday, November 12, 2014
PR Newswire - Wed Nov 05, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it will host a conference call and webcast on Wednesday, November 12, 2014 to discuss results for the period ended September 30, 2014 and to provide an update on current developments with respect to its clinical program for aramchol. GLMD: 6.80 (+0.03)
Galmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol's Effect on Endothelial Function
PR Newswire - Mon Sep 29, 8:13AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT(TM) devices and accessories from Itamar Medical Ltd. (TASE: ITMR) ("Itamar Medical" , a publicly-traded medical device company whose technology has been cleared by the U.S. Food and Drug Administration, or the FDA, for endothelial, or arterial, function assessment, which is a novel risk marker for cardiovascular disease. GLMD: 6.80 (+0.03)
Galmed's Aramchol Gets Fast-Track Designation in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:45PM CDT
Galmed Pharmaceuticals Ltd. (GLMD) announced that the FDA has granted fast track status to aramchol for the treatment of non-alcoholic steato-hepatitis.
LCI: 57.78 (-0.91), ENDP: 84.01 (+1.12), GLMD: 6.80 (+0.03), ENTA: 33.30 (-0.44)
Galmed Pharmaceuticals acquires US FDA's Fast Track Designation for Aramchol for NASH
M2 - Wed Sep 24, 6:24AM CDT
Biopharmaceutical company Galmed Pharmaceuticals (NasdaqCM :GLMD) reported on Tuesday the receipt of the US Food and Drug Administration's Fast Track Designation for aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.
GLMD: 6.80 (+0.03)
Market Maker Surveillance Report. RITT, JRJC, UQM, GLMD, SINO, ECTE, Winning Stocks With Lowest Price Friction For Tuesday, September 23rd 2014
M2 - Wed Sep 24, 3:42AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4582 companies with "abnormal" market making, 1424 companies with positive Friction Factors and 3854 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), China Finance Online Co Ltd (NASDAQ:JRJC), UQM Technologies Inc (NYSE:UQM), GOLD MEDAL RES LTD (NASDAQ:GLMD), Sino-Global Shipping America Ltd (NASDAQ:SINO), Echo Therapeutics Inc (NASDAQ:ECTE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ECTE: 2.62 (+0.06), JRJC: 5.46 (+0.16), GLMD: 6.80 (+0.03), UQM: 0.97 (+0.01), RITT: 1.29 (unch), SINO: 1.50 (unch)
Why Galmed Pharmaceuticals (GLMD) Stock Is Surging Today
at The Street - Tue Sep 23, 2:50PM CDT
Shares of Galmed Pharmaceuticals (GLMD) soared Tuesday after the company announced the FDA had given Fast Track Designation to its drug candidate aramchol.
GLMD: 6.80 (+0.03)
